Karuna Pays US$15 M Upfront for Goldfinch Bio’s TRPC4/5 Inhibitors
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 2 (Table of Contents)
Published: 24 Feb-2023
DOI: 10.3833/pdr.v2023.i2.2767 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In an attempt to bolster its neurology pipeline, Karuna Therapeutics has agreed to pay Goldfinch Bio US$15 M upfront and up to US$520 M in potential milestone payments for the latter’s investigational transient receptor potential canonical 4 and 5 (TRPC4/5) channel candidates...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS